Every 8-K that Vericel (VCEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCEL filings page.
Vericel Corporation reported strong second-quarter 2026 results, with total net revenue up 22% to $77.5 million. MACI revenue grew 23% to $65.5 million, and Burn Care revenue rose 22% to $12.0 million. Gross margin was 73%. Net income was $2.2 million, or $0.04 per diluted share, compared with a net loss a year earlier. Non-GAAP adjusted EBITDA was $14.9 million (19% of revenue), and free cash flow was $14.3 million. The company ended the period with approximately $227 million in cash and investments and no debt.
For the first half of 2026, revenue grew 26% to $145.9 million, with MACI at $121.9 million and Burn Care at $24.0 million, and adjusted EBITDA up 47% to $24.4 million. Vericel raised its 2026 guidance to $330–$340 million in total revenue and modestly increased both MACI and Burn Care outlooks, while reaffirming full-year gross margin of about 75% and adjusted EBITDA margin of about 27%. The board also authorized a $200 million share repurchase program, reflecting confidence in the company’s growth and cash generation.
Vericel Corporation filed an update reflecting a change to its corporate bylaws effective May 18, 2026. The Board of Directors approved an amendment so the bylaws now reference the company’s new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803. The filing notes that the Second Amended and Restated Bylaws are attached as an exhibit for full details, and that this change aligns the official corporate records with Vericel’s updated principal executive office address.
Vericel Corporation reported strong growth for the first quarter of 2026, with total revenue up 30% to $68.4 million compared to $52.6 million a year earlier. MACI net revenue rose 22% to $56.4 million and Burn Care revenue grew 91% to $12.0 million, including Epicel revenue growth of 119%.
Gross margin improved to 72%, helping narrow the net loss to $6.3 million, or $0.12 per diluted share, from $11.2 million, or $0.23 per share. Non-GAAP adjusted EBITDA increased 195% to $9.6 million, and free cash flow reached $15.1 million.
The company ended the quarter with approximately $211 million in cash and investments and no debt. Vericel raised its full-year 2026 revenue guidance by $10 million to a range of $326 to $336 million, with higher targets for both MACI and Burn Care.
Vericel Corporation reported the results of its annual shareholder meeting held on April 29, 2026. Shareholders elected seven directors — Robert Zerbe, Alan Rubino, Heidi Hagen, Kevin McLaughlin, Paul Wotton, Lisa Wright and Dominick Colangelo — each to one-year terms. Votes "for" each director ranged from 38,296,679 to 45,198,344, with broker non-votes of 2,162,887 on each nominee. Shareholders also approved, on a non-binding advisory basis, the compensation of Vericel's named executive officers, with 36,350,150 votes for, 9,725,057 against and 30,539 abstentions, plus 2,162,887 broker non-votes. In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, by 44,971,340 votes for, 3,275,442 against and 21,851 abstentions.
Vericel Corporation reported strong fourth-quarter and full-year 2025 results. Total 2025 revenue rose to $276.3 million, up 16% from 2024, driven by MACI revenue of $239.5 million, which grew 21%. Net income increased to $16.5 million, a 59% gain, and full-year gross margin improved to 74%.
In the fourth quarter, revenue grew 23% to $92.9 million, including $84.1 million from MACI, and gross margin reached a record 79%. The company ended 2025 with approximately $200 million in cash and investments and no debt. For 2026, Vericel projects total revenue of $316–$326 million, MACI revenue of $280–$286 million, gross margin of about 75%, and adjusted EBITDA margin of about 27%.
Vericel Corporation filed a report stating it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with a presentation scheduled for January 14, 2026, at 11:15 a.m. Pacific Time. In connection with the conference, the company issued a January 13, 2026 press release that provides preliminary, unaudited financial information for full-year 2025.
The press release includes estimates of Vericel’s 2025 revenue, net income, gross margin percentage, adjusted EBITDA margin, and its cash and investments balance as of December 31, 2025, along with additional financial and business updates. The company emphasizes that these figures are preliminary, have not been audited or reviewed by PricewaterhouseCoopers LLP, and may change, so stockholders are cautioned not to place undue reliance on them.
Vericel Corporation furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states the information in this report and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. Additional materials include the Inline XBRL cover page as Exhibit 104.